Allergan Inc (NYSE:AGN) Institutional Investor Positioning Change

September 30, 2018 - By Billy Entrekin

Allergan plc (NYSE:AGN) Logo

Sentiment for Allergan Inc (NYSE:AGN)

Allergan Inc (NYSE:AGN) institutional sentiment increased to 2 in 2018 Q2. Its up 1.50, from 0.5 in 2018Q1. The ratio is positive, as 6 hedge funds increased or opened new positions, while 3 reduced and sold their positions in Allergan Inc. The hedge funds in our partner’s database now have: 69,030 shares, down from 77,429 shares in 2018Q1. Also, the number of hedge funds holding Allergan Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 1 Increased: 3 New Position: 3.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $64.66 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

The stock decreased 0.03% or $0.05 during the last trading session, reaching $190.48. About 1.65M shares traded. Allergan plc (NYSE:AGN) has declined 17.68% since September 30, 2017 and is downtrending. It has underperformed by 33.30% the S&P500.

Analysts await Allergan plc (NYSE:AGN) to report earnings on November, 7. They expect $3.97 EPS, down 4.34 % or $0.18 from last year’s $4.15 per share. AGN’s profit will be $1.35B for 11.99 P/E if the $3.97 EPS becomes a reality. After $4.42 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -10.18 % negative EPS growth.

Grassi Investment Management holds 1.16% of its portfolio in Allergan plc for 43,335 shares. Callahan Advisors Llc owns 15,343 shares or 0.5% of their US portfolio. Moreover, Mitchell Mcleod Pugh & Williams Inc has 0.46% invested in the company for 3,935 shares. The Massachusetts-based Cubic Asset Management Llc has invested 0.1% in the stock. Staley Capital Advisers Inc, a Pennsylvania-based fund reported 1,400 shares.

Allergan plc (NYSE:AGN) Ratings Coverage

Ratings analysis reveals 64% of Allergan’s analysts are positive. Out of 11 Wall Street analysts rating Allergan, 7 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $15000 while the high is $25500. The stock’s average target of $205.09 is 7.67% above today’s ($190.48) share price. AGN was included in 16 notes of analysts from April 16, 2018. Mizuho maintained Allergan plc (NYSE:AGN) on Wednesday, May 30 with “Hold” rating. Wells Fargo maintained Allergan plc (NYSE:AGN) rating on Thursday, August 23. Wells Fargo has “Outperform” rating and $232 target. The company was maintained on Tuesday, May 1 by Wells Fargo. The stock of Allergan plc (NYSE:AGN) earned “Hold” rating by Cantor Fitzgerald on Monday, May 7. The firm has “Buy” rating by Cowen & Co given on Monday, April 16. The stock has “Outperform” rating by Credit Suisse on Thursday, May 3. As per Monday, September 17, the company rating was maintained by Raymond James. The rating was maintained by Bank of America with “Buy” on Tuesday, June 12. The firm earned “Overweight” rating on Thursday, August 23 by Morgan Stanley. The rating was maintained by Piper Jaffray on Thursday, May 31 with “Hold”.

More notable recent Allergan plc (NYSE:AGN) news were published by: which released: “Allergan announces FDA acceptance of supplemental new drug application for VRAYLAR” on September 26, 2018, also with their article: “Health Care Has Been On Fire. Will The Uptrend Continue?” published on September 07, 2018, published: “HighTide’s HTD1801 Fast Track’d for PSC” on September 27, 2018. More interesting news about Allergan plc (NYSE:AGN) were released by: and their article: “JMP: Changing Competitive Landscape Makes Revance Less Appealing” published on September 17, 2018 as well as‘s news article titled: “Allergan to acquire Bonti for $195M” with publication date: September 14, 2018.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: